tbuckley/cabot-search huggingface dataset:
MO19-3 Comparison of HER2 expression status between conventional HER2 test and VENTANA HER2 (4B5) of metastatic breast cancer
Authors: N. Tokudome, T. Sugino, S. Nishimura, E. Bekku, T. Hayashi, Y. Tadokoro, K. Takahashi, K. Nakashima, T. Uematsu
Journal: Annals of Oncology (2024)
MO13-1 Potential value of NLR for NIVO + IPI in MSI-H gastric cancer: sub-analysis of the NO LIMIT study (WJOG13320G/CA209-7W7)
Authors: N. Sugimoto, H. Kawakami, S. Kadowaki, A. Makiyama, M. Tsuda, K. Hirata, N. Machida, H. Hara, H. Hirano, T. Esaki, Y. Komatsu, S. Hironaka, Y. Chiba, K. Muro
Journal: Annals of Oncology (2024)
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer
Authors: H. Okumura, K. Takemura, H. Kono, E. Toda, H. Ozaki, M. Kuno, S. Watanabe, K. Yamamoto, T. Yamaguchi, K. Suyama, Y. Miura, Y. Tanabe
Journal: Annals of Oncology (2024)
O14-2 Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
Authors: Y. Ohe, V. Subbiah, V. Sukrithan, B. Robinson, B. Deschler-Baier, T. Iwasa, K. Ohashi, K. Goto, M. Nishio, M. Satouchi, K. Nakamura, S. Ashiguchi, Y. Lin, S. Szymczak, A. Drilon
Journal: Annals of Oncology (2024)
MO14-4 Improving survival outcomes with ambulatory chemotherapy in metastatic colorectal cancer in Ramathibodi Hospital
Authors: P. Chansriwong, N. Sripaiboonkij Thokanit, S. Sirilerttrakul, N. Wannakansophon, P. Tangteerakoon, S. Vongterapak, S. Ckumdee, M. Jirajarus, E. Sirachainan
Journal: Annals of Oncology (2024)
P113-4 Progression-free survival of niraparib in patients with platinum-sensitive recurrent ovarian cancer: meta-analysis
Authors: N.B.S.A. Purushotama, C.J. Budianto, M.Z. Sabran, C.E.O.L. Hutauruk, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
O16-5 Epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 longer-term data
Authors: K. Izutsu, T. Kumode, J. Yuda, H. Nagai, Y. Mishima, Y. Suehiro, K. Yamamoto, T. Fujisaki, K. Ishitsuka, K. Ishizawa, T. Ikezoe, M. Nishikori, D. Akahane, J. Fujita, P. Jafarinasabian, H. Noguchi, J. Buchbjerg, E. Favaro, N. Fukuhara
Journal: Annals of Oncology (2024)
MO9-3 Ribociclib plus letrozole vs. letrozole alone in HR+/HER2− advanced breast cancer: a systematic review and meta-analysis
Authors: M.Z. Sabran, C.E.O.L. Hutauruk, C.J. Budianto, N.B.S.A. Purushotama, J.V. Lee, M.G. Wibisono, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P93-4 A case of lung adenocarcinoma with EGFR L858R caused by a rare 2-base deletion-insertion mutation detected by NGS
Authors: T. Fujiwara, T. Kitajima, Y. Tono, J. Tsuboi, A. Yagi, K. Saito, S. Tamaru, Y. Okugawa, T. Mizuno, T. Kobayashi
Journal: Annals of Oncology (2024)
MO2-1 Dosimetric comparison: volumetric modulated arc therapy and stereotactic body radiotherapy for prostate cancer patients
Authors: E.Y.W. Cheung, G.C.K. Chan, R.W.S. Ma, E.Y. Nip, K. Fong, J.S.Y. Wong, C.N.K. Lam
Journal: Annals of Oncology (2024)
MO63-4 Utility of IHC-based markers for predicting pathological complete response in early-stage triple-negative breast cancer
Authors: C. Funasaka, T. Kogawa, N. Sakamoto, S. Kusuhara, T. Nakao, C. Kondoh, H. Nakajima, K. Harano, N. Matsubara, A. Hosono, Y. Naito, M. Shimokawa, R. Watanuki, Y. Yamashita, C. Yamauchi, T. Onishi, G. Ishii, T. Mukohara
Journal: Annals of Oncology (2024)
MO52-6 Results of treatment for FIGO stage I-II vulvar squamous cell carcinoma at Viet Nam National Cancer Hospital
Authors: A. Quang Nguyen, C. Tri Le, H. Thi Pham, L. Thanh Tran, H. Van Truong, P. Thanh Vu, T. Van Nguyen, H. Viet Tran, D. Ba Nguyen
Journal: Annals of Oncology (2024)
MO23-4 A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy
Authors: A. Doi, Y. Kaga, Y. Kubota, H. Takeda, K. Umemoto, H. Arai, Y. Horie, T. Ogura, N. Izawa, E. Horibe, K. Tanzawa, Y. Sunakawa
Journal: Annals of Oncology (2024)
MO4-1 Clinical outcome of peptide receptor radionuclide therapy for patients with advanced neuroendocrine tumor
Authors: T. Shibuki, H. Imaoka, H. Suzuki, D. Kano, K. Takahashi, K. Yanagisawa, H. Hirata, T. Akimoto, M. Ikeda
Journal: Annals of Oncology (2024)
P100-1 Clinicopathological and molecular analysis of cancer of unknown primary with chromatin remodeling gene alterations
Authors: Y. Tono, K. Sukeno, A. Tsunoda, M. Okayama, H. Oka, H. Oda, K. Saito, S. Tamaru, Y. Yamashita, M. Taniguchi, M. Ikejiri, H. Imai, T. Mizuno
Journal: Annals of Oncology (2024)
P110-4 Low compared to high dose regiment of induction chemotherapy in nasopharingeal cancer: a systematic review meta-analysis
Authors: A. Kurniawan, A. Tancherla, F. Wijovi, D. Adella Halim, R. Cahyanur, A. Giselvania, N. Novianti Siregar, C. Sari, D. Astri Rivera Amelia, D. Djatnika, M. Arman Nasution, D. Priantono
Journal: Annals of Oncology (2024)
MO2-6 Does the starting dose of cabozantinib for metastatic renal cell carcinoma affect treatment efficacy/adverse events?
Authors: N. Miura, S. Haga, K. Nishimura, T. Fukumoto, Y. Miyauchi, T. Kikugawa, R. Kono, K. Hashine, I. Ninomiya, T. Noda, T. Tacho, T. Saika
Journal: Annals of Oncology (2024)
P114-6 Efficacy and safety of pembrolizumab in patients with uterine neoplasms: a systematic review
Authors: S.A. Nariswari, J. Octavian, V.A. Laiman, T.T. Nathania, V.T. Herwi, B. Davina, S. Kosayuz, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
P98-1 Efficacy of vemurafenib in patients with melanoma: a systematic review
Authors: R. Christopher Harliman, N. Bagus Satcitta Ananda Purushotama, C. Janice Budianto, M. Zuhriansyah Sabran, A. Syah, A. Kurniawan
Journal: Annals of Oncology (2024)
MO20-4 Extranodal lesions of DLBCL at the 1st relapse might predict CNS lesions in the 2nd relapse
Authors: Y. Okabe, Y. Hori, S. Tabata, T. Hiroi, Y. Yamashita, H. Hosoi, T. Mushino, S. Murata, T. Sonoki
Journal: Annals of Oncology (2024)
MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC
Authors: K. Azuma, H. Imai, T. Yamaguchi, T. Kijima, K. Kishi, K. Fujita, H. Saito, Y. Shiraishi, J. Tanizaki, Y. Takashima, Y. Tambo, S. Watanabe, O. Hataji, Y. Toi, T. Fukuhara, T. Ohsugi, H. Kuroda, Y. Ohe, H. Horinouchi
Journal: Annals of Oncology (2024)
MO41-4 Importance of local control of primary cardiac sarcomas: a report of 5 cases
Authors: N. Nishitarumizu, S. Kinoshita, Y. Oshima, K. Hirade, M. Takemoto, M. Asaoka, T. Sanda, S. Iida, H. Komatsu
Journal: Annals of Oncology (2024)
MO4-4 Short-term outcomes of nivolumab plus chemotherapy for advanced gastric neuroendocrine cell carcinoma
Authors: M. Onishi, M. Furuta, T. Hama, K. Furusawa, K. Hayashi, Y. Inokuchi, J. Furuse, N. Machida, S. Maeda
Journal: Annals of Oncology (2024)
P103-9 Partial response to docetaxel and gemcitabine chemotherapy in a patient with HG-ESS stage IV: a case report
Authors: F. Yamamoto, T. Hasegawa, H. Ikebe, T. Yamasaki, N. Ohata, M. Ishizaka, A. Suzuki, Y. Hagiwara, A. Yumori, A. Mochimaru, M. Ishikawa
Journal: Annals of Oncology (2024)
<i>Candida tropicalis</i> -derived vitamin B3 exerts protective effects against intestinal inflammation by promoting IL-17A/IL-22-dependent epithelial barrier function
Authors: Ha T Doan, Li-Chieh Cheng, Yi-Ling Chiu, Yuan-Kai Cheng, Cheng-Chih Hsu, Yee-Chun Chen, Hsiu-Jung Lo, Hao-Sen Chiang
Journal: Gut Microbes (2024)

a prevalent gut commensal fungus in healthy individuals - contributes to intestinal health and disease. However, how commensal
How important are fatty acids in human health and can they be used in treating diseases?
Authors: Leon M. T. Dicks
Journal: Gut Microbes (2024)

Most of the short-chain fatty acids (SCFAs) are produced by Bifidobacterium, Lactobacillus, Lachnospiraceae, Blautia, Coprococcus, Roseburia, Facealibacterium and Oscillospira. Butyrate (C4H7O2−) supplies 70% of energy to intestinal epithelial cells (IECs), supports tight-junction protein formation, induces the production of inflammatory cytokines, and inhibits histone deacetylase (HDAC). Butyrate is also associated with the recovery of brain trauma, improvement of dementia, the alleviation of autoimmune encephalitis, and several intestinal disorders. Low levels of SCFAs are associated with hypertension, cardiovascular disease (CVD), strokes, obesity, and diabetes mellitus. Cis-palmitoleic acid (C16H30O2), a mono-unsaturated fatty acid (MUFA), increases insulin sensitivity and reduces the risk of developing CVD. Lipokine palmitoleic acid reduces the expression of pro-inflammatory cytokines IL-1β (pro-IL1β), tumor necrosis factor α (TNF-α), and isoleucine 6 (IL-6). Polyunsaturated fatty acids (PUFAs), such as omega-3 and omega-6, are supplied through the diet. The conversion of PUFAs by cyclooxygenases (COX) and lipoxygenases (LOX) leads to the production of anti-inflammatory prostaglandins and leukotrienes. Oxidation of linoleic acid (LA, C18H32O2), an omega-6 essential fatty acid, leads to the formation of 13-hydroperoxy octadecadienoic acid (13-HPODE, C18H32O4), which induces pro-inflammatory cytokines. Omega-3 PUFAs, such as eicosapentaenoic acid (EPA, C20H30O2) and docosahexaenoic acid (DHA, C22H32O2), lower triglyceride levels, lower the risk of developing some sort of cancers, Alzheimer's disease and dementia. In this review, the importance of SCFAs, MUFAs, PUFAs, and saturated fatty acids (SFAs) on human health is discussed. The use of fatty acids in the treatment of diseases is investigated.
Lactobacillaceae differentially impact butyrate-producing gut microbiota to drive CNS autoimmunity
Authors: Theresa L. Montgomery, Lucinda C. Toppen, Korin Eckstrom, Eamonn R. Heney, Josephine J. Kennedy, Matthew J. Scarborough, Dimitry N. Krementsov
Journal: Gut Microbes (2024)

Short-chain fatty acids (SCFAs), produced by the gut microbiota, are thought to exert an anti-inflammatory effect on the host immune system. The levels of SCFAs and abundance of the microbiota that produce them are depleted in multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS). The mechanisms leading to this depletion are unknown. Using experimental autoimmune encephalomyelitis (EAE) as a model for MS, we have previously shown that gut microbiomes divergent in their abundance of specific commensal
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock – a Secondary Analysis of the DanGer Shock Trial
Authors: Elric Zweck, Christian Hassager, Rasmus P. Beske, Lisette O. Jensen, Hans Eiskjær, Norman Mangner, Amin Polzin, P. Christian Schulze, Carsten Skurk, Peter Nordbeck, Peter Clemmensen, Vasileios Panoulas, Sebastian Zimmer, Andreas Schäfer, Malte Kelm, Thomas Engstrøm, Lene Holmvang, Anders Junker, Henrik Schmidt, Christian J. Terkelsen, Axel Linke, Ralf Westenfeld, Jacob E. Møller
Journal: Circulation (2024)

Background: In the Danish–German Cardiogenic Shock (DanGer Shock) trial, use of a microaxial flow pump (mAFP) in patients with ST-segment elevation myocardial infarction (STEMI)-related CS led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed. Methods: In this international, randomized, open label, multicenter trial, 355 adult patients with STEMI-CS were randomized to mAFP (N=179) or standard care alone (N=176). AKI was defined according to Risk, Injury, and Failure, sustained Loss and End-stage kidney disease (RIFLE) criteria and assessed using logistic regression models. Use of RRT was assessed accounting for the competing risk of death using Fine-Gray subdistribution hazard models. Results: AKI (RIFLE≥1) was recorded in 110 patients (61%) in mAFP group and 79 (45%) in control group (p&lt;0.01); RRT was used in 75 (42%) and 47 (27%) patients, respectively (p&lt;0.01). About 2/3 of the RRTs were initiated within the first 24h from admission (n=48 (64%) in mAFP group, n=31 (66%) in control group). Occurrence of AKI and RRT were associated with higher 180-day mortality in both study arms. At 180 days, all patients alive were free of RRT. mAFP use was associated with higher rates of RRT, even when accounting for competing risk of death (subdistribution hazard: 1.67 [1.18-2.35]). This association was largely consistent among prespecified subgroups. Allocation to mAFP was associated with lower 180-day mortality irrespective of AKI or RRT (p=0.8 for interaction). Relevant predictors of AKI in both groups comprised reduced left ventricular ejection fraction, baseline kidney function, shock severity, bleeding events, and positive fluid balance. In addition, predictors of AKI specific to mAFP were suction events, higher pump speed, and longer duration of support. Conclusions: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease
Authors: Michael J. Foley, Christopher A. Rajkumar, Fiyyaz Ahmed-Jushuf, Florentina Simader, Shayna Chotai, Henry Seligman, Krzysztof Macierzanka, John R. Davies, Thomas R. Keeble, Peter O'Kane, Peter Haworth, Helen Routledge, Tushar Kotecha, Gerald Clesham, Rupert Williams, Jehangir Din, Sukhjinder S. Nijjer, Nick Curzen, Manas Sinha, Ricardo Petraco, James Spratt, Sayan Sen, Graham D. Cole, Frank E. Harrell Jr., James P. Howard, Darrel P. Francis, Matthew J. Shun-Shin, Rasha Al-Lamee
Journal: Circulation (2024)

Background: The Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina (ORBITA-2) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease (CAD). Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI, however their ability to predict placebo-controlled angina improvement is unknown. Methods: Participants with angina, ischemia, and stable CAD were enrolled and antianginal medications were stopped. Participants reported angina episodes daily for 2 weeks using the ORBITA-app. At the research angiogram, FFR and iFR were measured. After sedation and auditory isolation, participants were randomized to PCI or placebo, before entering a 12-week blinded follow-up phase with daily angina reporting. The ability of FFR and iFR, analyzed as continuous variables, to predict the placebo-controlled effect of PCI, was tested using Bayesian proportional odds modelling. Results: Invasive physiology data were available in 279 patients (140 PCI and 139 placebo). The median (IQR) age was 65 years (59.0 to 70.5) and 223 (79.9%) were male. Median FFR was 0.60 (0.46 to 0.73) and median iFR was 0.76 (0.50 to 0.86). The lower the FFR or iFR, the greater the placebo-controlled improvement with PCI across all endpoints. There was strong evidence that a patient with an FFR at the lower quartile would have a greater placebo-controlled improvement in angina symptom score with PCI than a patient at the upper quartile (FFR 0.46 vs. 0.73: OR 2.01, 95% CrI 1.79 to 2.26, Pr(Interaction)&gt;99.9%). Similarly, there was strong evidence that a patient with an iFR at the lower quartile would have a greater placebo controlled improvement in angina symptom score with PCI than a patient with an iFR at the upper quartile (iFR 0.50 vs. 0.86: OR 2.13, 95% CrI 1.87 to 2.45, Pr(Interaction) &gt;99.9%). The relationship between benefit and physiology was seen in both Rose angina and Rose nonangina. Conclusions: Physiological stenosis severity, as measured by FFR and iFR, predicts placebo-controlled angina relief from PCI. Invasive coronary physiology can be used to target PCI to those patients who are most likely to experience benefit.
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Authors: Jonathan Barratt, Sean J. Barbour, Robert M. Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard K.S. Phoon, Harmeet Singh, Vladimír Tesař, Richard Lafayette
Journal: Journal of the American Society of Nephrology (2024)

Key Points Participants who completed a 36-week double-blind study of atacicept were eligible for a 60-week, open-label extension study. Atacicept 96-week treatment resulted in sustained reductions in galactose-deficient IgA1, hematuria, and urine protein-creatinine ratio. The slope of the eGFR was similar to that observed in the general population without kidney disease. Background B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) play key roles in the pathogenesis of IgA nephropathy. Atacicept is a novel fully humanized fusion protein, self-administered at home by subcutaneous injection, that binds and inhibits BAFF and APRIL. By inhibiting BAFF and APRIL, atacicept targets the underlying B-cell–mediated pathogenesis driving disease progression. This study evaluated the long-term efficacy and safety of atacicept in patients with IgA nephropathy over 96 weeks. Methods Participants with IgA nephropathy who received atacicept (25, 75, or 150 mg) or placebo in a 36-week phase 2b, randomized, blinded trial were enrolled in an open-label extension study and received atacicept 150 mg for an additional 60 weeks. Key efficacy outcomes were changes in galactose-deficient IgA1 (Gd-IgA1), percentage of participants with hematuria, urine protein-creatinine ratio (UPCR), and eGFR over 96 weeks. Long-term safety data were also evaluated. Results There were 113 participants (67 [59%] male; 46 [41%] female) who ranged in age from 18 to 67 years who received ≥1 atacicept dose. Over 96 weeks, safety data demonstrated that atacicept was generally well tolerated. There were also sustained reductions (mean±SEM) in Gd-IgA1 (−66%±2%), percentage of participants with hematuria (−75%; 95% confidence intervals, −87 to −59; in participants with baseline hematuria), and UPCR (−52%±5%). The mean annualized slope of eGFR was −0.6±0.5 ml/min per 1.73 m 2 through 96 weeks. Conclusions Atacicept was well tolerated over the duration of the study. Atacicept treatment reduced Gd-IgA1, hematuria, and UPCR with stabilization of eGFR through 96 weeks. Clinical Trial registry name and registration number: Atacicept in Subjects with IgA Nephropathy (ORIGIN 2), NCT04716231.
From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy
Authors: Sydney C.W. Tang, Girish N. Nadkarni
Journal: Journal of the American Society of Nephrology (2024)

1Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong 2Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 3The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 4Division of Data Driven and Digital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York Correspondence: Prof. Girish N. Nadkarni, email: [email protected] See related articles, "Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy," "The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial," "Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial," on pages XXX–XXX, XXX–XXX, and XXX–XXX, respectively.
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention
Authors: Felice Gragnano, David van Klaveren, Dik Heg, Lorenz Räber, Mitchell W. Krucoff, Sergio Raposeiras-Roubän, Jurriën M. ten Berg, Sergio Leonardi, Takeshi Kimura, Noé Corpataux, Alessandro Spirito, James B. Hermiller, Emad Abu-Assi, Dean Chan Pin Yin, Jaouad Azzahhafi, Claudio Montalto, Marco Galazzi, Sarah Bär, Raminta Kavaliauskaite, Fabrizio D'Ascenzo, Gaetano M. De Ferrari, Hirotoshi Watanabe, Philippe Gabriel Steg, Deepak L. Bhatt, Paolo Calabrò, Roxana Mehran, Philip Urban, Stuart Pocock, Stephan Windecker, Marco Valgimigli
Journal: Circulation (2024)

Background: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria. Methods: The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p&lt;0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort. Results: The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71–0.74) at apparent validation, 0.72 (95% CI, 0.70–0.73) at cross-validation, 0.74 (95% CI, 0.68–0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66–0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability. Conclusions: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.